IDEAYA Biosciences, Inc. (IDYA) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low6.3·High6.3
P/B Ratio
↑
2.49
-6% vs avg
5yr avg: 2.64
30Y Low1.5·High3.3
ROE
↑
-10.9%
↓+48% vs avg
5yr avg: -21.0%
30Y Low-163%·High-11%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IDYA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
IDEAYA Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.5B | $3.1B | $2.1B | $2.0B | $753M | $833M | $346M | $152M | — | — |
| Enterprise Value | $2.4B | $3.0B | $2.0B | $1.9B | $688M | $747M | $281M | $124M | — | — |
| P/E Ratio → | -22.45 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 11.54 | 13.99 | 299.88 | 87.52 | 14.79 | 29.83 | 17.71 | — | — | — |
| P/B Ratio | 2.49 | 2.99 | 1.98 | 3.30 | 2.15 | 2.76 | 1.75 | 1.51 | — | — |
| P/FCF | — | — | — | — | — | — | 6.30 | — | — | — |
| P/OCF | — | — | — | — | — | — | 6.24 | — | — | — |
P/E links to full P/E history page with 30-year chart
IDYA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.60 | 290.56 | 80.92 | 13.51 | 26.72 | 14.37 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 5.11 | — | — | — |
IDYA Profitability
Margins and return-on-capital ratios measuring operating efficiency
IDEAYA Biosciences, Inc. earns an operating margin of -72.8%. Operating margins have expanded from -574.9% to -72.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -10.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.9% | 97.9% | 45.2% | 82.9% | 95.9% | 93.8% | 92.9% | — | — | — |
| Operating Margin | -72.8% | -72.8% | -4671.1% | -574.9% | -122.7% | -179.9% | -180.9% | — | — | — |
| Net Profit Margin | -52.0% | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | -176.6% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -10.9% | -10.9% | -32.7% | -23.3% | -18.0% | -19.9% | -23.1% | -163.2% | — | — |
| ROA | -10.2% | -10.2% | -31.0% | -21.8% | -15.2% | -14.6% | -16.8% | -40.1% | -60.2% | -67.9% |
| ROIC | -12.4% | -12.4% | -33.6% | -26.8% | -18.8% | -21.7% | -25.7% | -1818.4% | — | — |
| ROCE | -15.0% | -15.0% | -38.5% | -27.5% | -18.1% | -16.9% | -19.3% | -44.9% | -68.6% | -96.0% |
IDYA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $113M exceeds total debt of $28M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.02 | 0.00 | 0.01 | 0.02 | 0.03 | 0.07 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | -0.06 | -0.25 | -0.19 | -0.29 | -0.33 | -0.27 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -1.19 | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($113M) exceeds total debt ($28M)
IDYA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
IDEAYA Biosciences, Inc.'s current ratio of 11.34x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 19.65x to 11.34x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.34 | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 | 7.47 | 14.65 | 16.75 | 5.58 |
| Quick Ratio | 11.34 | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 | 7.47 | 14.65 | 16.75 | 5.58 |
| Cash Ratio | 10.87 | 10.87 | 14.68 | 19.38 | 11.50 | 5.46 | 7.34 | 14.26 | 16.62 | 5.41 |
| Asset Turnover | — | 0.20 | 0.01 | 0.04 | 0.13 | 0.07 | 0.07 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 0.16 | 0.28 | 1.51 | 14.41 | 35.07 | — | — | — |
IDYA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
IDEAYA Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 15.9% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $88M | $82M | $58M | $41M | $35M | $25M | $20M | $14M | $14M |
Peer Comparison
Compare IDYA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IDYAYou | $3B | -22.5 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 TPVG | $226M | 4.6 | 8.9 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 AGEN | $137M | -1144.1 | — | — | 90.3% | -18.0% | — | — | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 PMVP | $77M | -1.3 | — | — | — | — | -29.2% | -38.0% | — |
 TNGX | $3B | -27.1 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 MGNX | $191M | -2.6 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 NUVL | $7B | -26.5 | — | — | — | — | -29.5% | -32.6% | — |
 ARQT | $3B | -185.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See IDYA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IDYA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IDYA vs TPVG
Side-by-side business, growth, and profitability comparison vs TriplePoint Venture Growth BDC Corp..
Start ComparisonIDYA — Frequently Asked Questions
Quick answers to the most common questions about buying IDYA stock.
What is IDEAYA Biosciences, Inc.'s P/E ratio?
IDEAYA Biosciences, Inc.'s current P/E ratio is -22.5x. This places it at the 50th percentile of its historical range.
What is IDEAYA Biosciences, Inc.'s ROE?
IDEAYA Biosciences, Inc.'s return on equity (ROE) is -10.9%. The historical average is -41.6%.
Is IDYA stock overvalued?
Based on historical data, IDEAYA Biosciences, Inc. is trading at a P/E of -22.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are IDEAYA Biosciences, Inc.'s profit margins?
IDEAYA Biosciences, Inc. has 97.9% gross margin and -72.8% operating margin.